On 23 December 2025, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Hanx Bio, 3378.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 586 million. CBI is honored to participate in the due diligence work for this IPO Project.

Hanx Bio is a China-based company mainly engaged in the discovery, development and commercialization of immuno-oncology therapy. The product pipeline mainly comprises clinical stage drug candidates focused on oncology, including HX009, HX301 and HX044, as well as preclinical stage drug candidates including antibody drug conjugate, bispecific antibody and monoclonal antibody for autoimmune and oncology market.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, suppliers and related parties, etc. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reference check, reputation intelligence and related company search. The due diligence project globally covered 7 countries and regions, including China, Hong Kong, Australia, France, and the United States, etc.